MedPath

Effect of Docosahexaenoic Acid on ROP in premature newbor

Phase 3
Completed
Conditions
Retinopathy of prematurity.
H35.1
Retinopathy of prematurity
Registration Number
IRCT20211226053528N1
Lead Sponsor
Iran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
124
Inclusion Criteria

Obtaining parental consent to participate in the study
Premature newborn weighing less than1500 gr

Exclusion Criteria

Infants with asphyxia (umbilical cord pH less than 7 and BE less than -16)
IUGR infants
Definitive sepsis (positive blood culture),
Newborns with severe congenital chromosomal abnormalities
Newborns with congenital heart disease
Infants with metabolic diseases
Newborns with hypotension need vasodilators

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Retinopathy stage (based on disease severity). Timepoint: before intervention and 1month after intervention. Method of measurement: Based on the severity of the disease (1-5 stages) by an ophthalmologist.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath